AZ Goes Into The MYSTIC And Finds Positives For Imfinzi

Against all the odds, AstraZeneca still has hopes for Imfinzi in first-line NSCLC with data from the failed MYSTIC trial suggesting strong survival in patients with a high tumour mutation burden.